Levomepromazine
As of the edition of 20 October 2026, Levomepromazine is a small molecule: marketed, first approved in 1958 (CH); acts on DRD2, DRD3 and DRD4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1988
- Kind
- Small molecule
- Brand name
- Levoprome
- First approved
- 18 February 1958 (CH)
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- NEURAXPHARM FRANCE; 5 holders in all
- Registered trials
- 1, 1 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 1 |